SAB Biotherapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview

SAB Biotherapeutics

27/03/2024 11:18

* SAB Biotherapeutics Inc  SABS.OQ   SABS.O  is expected
to report
resultson March 29 (estimated) for the period ending December
31 2023
    * 
    * ​LSEG's mean analyst estimate for SAB Biotherapeutics Inc
is for
a loss of 62 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for SAB
Biotherapeutics Inc is $20.00​, above​ its last closing price
of $4.17. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.16       -1.17      -1.00     Beat    14.3
 Jun. 30 2023  -1.48       -1.45      -1.40     Beat    3.4
 Mar. 31 2023  -0.80       -0.80      -1.50     Missed  -87.5​
 Dec. 31 2022              -0.35      -0.20     Beat    42.9
 ​​Sep.        -1.90       -1.60      -1.60     Met     0
 30 2022                                                
 Jun. 30 2022  -1.70       -1.70      -1.10     Beat    35.3​
 Mar. 31 2022  -1.73       -1.65      0.20      Beat    112.1
 Dec. 31 2021  -1.04       -1.10      -6.60     Missed  -500
 This summary was machine generated March 27 at 11:18 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)